Revance Therapeutics (RVNC) versus Its Rivals Financial Survey

Revance Therapeutics (NASDAQ: RVNC) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Revance Therapeutics to related businesses based on the strength of its risk, profitability, earnings, institutional ownership, analyst recommendations, dividends and valuation.


This table compares Revance Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Revance Therapeutics -37,161.00% -67.85% -57.91%
Revance Therapeutics Competitors -5,300.58% -432.11% -40.00%

Earnings and Valuation

This table compares Revance Therapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Revance Therapeutics $300,000.00 -$89.27 million -7.28
Revance Therapeutics Competitors $284.30 million $34.29 million 142.58

Revance Therapeutics’ rivals have higher revenue and earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Revance Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Revance Therapeutics’ rivals have a beta of 5.83, suggesting that their average stock price is 483% more volatile than the S&P 500.

Institutional and Insider Ownership

88.7% of Revance Therapeutics shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 18.9% of Revance Therapeutics shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Revance Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revance Therapeutics 0 0 6 0 3.00
Revance Therapeutics Competitors 839 3190 11555 230 2.71

Revance Therapeutics currently has a consensus target price of $36.00, indicating a potential upside of 30.20%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.83%. Given Revance Therapeutics’ rivals higher probable upside, analysts plainly believe Revance Therapeutics has less favorable growth aspects than its rivals.


Revance Therapeutics rivals beat Revance Therapeutics on 7 of the 12 factors compared.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

What are top analysts saying about Revance Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Revance Therapeutics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit